CCHT(SZ:000661) Ge Long Hui A P P·2025-08-21 14:24Core Viewpoint - Changchun High-tech Industry (Group) Co., Ltd. announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received the acceptance notice for the clinical trial application of GenSci143 from the National Medical Products Administration, indicating progress in the development of a novel dual-target antibody-drug conjugate for cancer treatment [1] Group 1 - GenSci143 is a dual-specific antibody-drug conjugate targeting B7-H3 and PSMA, designed to provide both targeted chemotherapy and tumor immunotherapy [1] - The mechanism of GenSci143 involves internalization into lysosomes upon binding to B7-H3 or PSMA, releasing a TOPO-I inhibitor toxin to kill B7-H3 positive, PSMA positive, and dual-positive tumor cells [1] - The dual-target approach of B7-H3 and PSMA aims to overcome tumor heterogeneity and resistance caused by reduced expression of single targets, potentially benefiting a larger patient population with more durable anti-tumor efficacy [1] Group 2 - GenSci143 utilizes proprietary linker technology, which enhances the potency of the toxin and the stability of the linker in plasma, contributing to stronger tumor-killing effects and improved safety profiles [1] - The innovative dual-target design, stable linker technology, and efficient cell-killing mechanism of GenSci143 may offer new treatment options for various solid tumors expressing B7-H3 and/or PSMA [1]